Kazia Therapeutics EV / EBITDA
Was ist das EV / EBITDA von Kazia Therapeutics?
EV / EBITDA von Kazia Therapeutics Limited ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Kazia Therapeutics
Was macht Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Unternehmen mit ev / ebitda ähnlich Kazia Therapeutics
- NeonMind Biosciences hat EV / EBITDA von N/A
- Lumos Diagnostics hat EV / EBITDA von N/A
- Bluewater Acquisition Corp hat EV / EBITDA von N/A
- Guyana Goldstrike Inc hat EV / EBITDA von N/A
- BrewBilt Manufacturing hat EV / EBITDA von N/A
- Sable Resources hat EV / EBITDA von N/A
- Kazia Therapeutics hat EV / EBITDA von N/A
- engage:BDR hat EV / EBITDA von N/A
- Viaan Industries hat EV / EBITDA von N/A
- Antera Ventures Ii Corp hat EV / EBITDA von N/A
- MacDonald Mines Exploration hat EV / EBITDA von N/A
- Sihayo Gold hat EV / EBITDA von N/A
- Fabled Copper hat EV / EBITDA von N/A